U.S. FDA declines to approve Revance’s frown-line treatment
Original source: https://www.investing.com/news/stock-market-news/us-fda-declines-to-approve-revances-frownline-treatment-2645689
Read More »Are Penny Stocks High Risk?
Penny stocks are high risk mainly due to the lack of liquidity and company information as well as the high volatility associated with lower priced stocks. Many day traders…
Read More »How High Can A Penny Stock Go?
Just like mid and large cap stocks, there is no limit to how high a penny stock can go. Many massive, well-established companies were once trading for less than…
Read More »Mid-Week Market Podcast – December 16
HotForex · Midweek Market Update – December 16 2020 Unemployment remains the significant global issue. US weekly claims once again had a poor week, missing expectations significantly and registering…
Read More »US Equity Markets Cooler, Swissy firmer, GBP weaker
US equity markets have opened weaker, as doubts over the outlook continue to fester. Specifically, rising virus cases in the US and the resultant increase in shutdowns, the lack of…
Read More »CAD Retail Sales Beat, Oil & Equities Dip
Canada’s retail sales jumped 1.1% in September while the ex-autos sales aggregate grew 1.0%. Both measures easily beat expectations for modest gains, and marked the fifth consecutive monthly increase…
Read More »Trump whines about a political hit job re vaccine safety rules
Trump with his next tweet, moaning about a hit job or something. Trump is referring to the US FDA wanting to test vaccine candidates for efficacy and safety before approving…
Read More »